翰森制药(03692)：HS-10365胶囊上市许可申请获国家药品监督管理局受理

Core Viewpoint - Hansoh Pharmaceutical (03692) has received acceptance for its New Drug Application (NDA) for the innovative drug HS-10365 capsule by the National Medical Products Administration (NMPA) in China, aimed at treating adult patients with RET gene fusion-positive locally advanced or metastatic non-small cell lung cancer (NSCLC) [1] Group 1 - The NDA for HS-10365 was accepted on October 23, 2025 [1] - The drug targets a specific patient population with RET gene fusion-positive NSCLC [1]